The Pursuit of an Optimal Diagnostic Strategy
The future depends on collaboration between pharma and diagnostics companies to implement strategies that accelerate innovation, ensure regulatory alignment, and deliver local access at global scale.
From Single-Site to Global Scale: A Hybrid Future for CDx
Sponsored content brought to you by Precision oncology is reshaping cancer care, with genomics increasingly guiding diagnosis and therapeutic decisions.
At the heart of this transformation are companion diagnostics (CDx), essential tools to ensure patients receive the right treatment at the right time.
However, despite remarkable scientific advances, pharmaceutical companies face a persistent challenge: how to bring precision therapies to market faster while ensuring efficiency, accuracy, and broad patient access?
To meet these demands, CDx pathways must evolve to align with regulatory requirements, offer short turnaround times (TAT) from development to commercialization, scale effectively, and guarantee equitable access worldwide.
Precision oncology is reshaping cancer care, with genomics increasingly guiding diagnosis and therapeutic decisions.
Author's summary: Collaboration between pharma and diagnostics companies is key.